Diabetes, metabolic syndrome and dyslipidemia in people living with HIV in Africa: re-emerging challenges not to be forgotten
NE Husain, SK Noor, WM Elmadhoun… - HIV/AIDS-Research …, 2017 - Taylor & Francis
Background The current challenge in managing people living with human immunodeficiency
virus (PLWHIV) includes the identification and monitoring for comorbid health risks …
virus (PLWHIV) includes the identification and monitoring for comorbid health risks …
The CCL2/CCR2 axis in the pathogenesis of HIV-1 infection: a new cellular target for therapy?
D Angela Covino, M Sabbatucci… - Current drug targets, 2016 - ingentaconnect.com
The identification of chemokine receptors as necessary co-receptors for HIV entry into target
cells represented a breakthrough in the understanding of the pathogenesis of this viral …
cells represented a breakthrough in the understanding of the pathogenesis of this viral …
Endocrinological aspects of HIV infection
FS Mirza, P Luthra, L Chirch - Journal of Endocrinological Investigation, 2018 - Springer
Purpose Patients with human immunodeficiency virus (HIV) are living longer with effective
antiretroviral therapies and are enjoying near normal life span. Therefore, they are …
antiretroviral therapies and are enjoying near normal life span. Therefore, they are …
HIV, vascular risk factors, and cognition in the combination antiretroviral therapy era: a systematic review and meta-analysis
EC McIntosh, K Tureson, LJ Rotblatt… - Journal of the …, 2021 - cambridge.org
Objectives: Mounting evidence indicates that vascular risk factors (VRFs) are elevated in HIV
and play a significant role in the development and persistence of HIV-associated …
and play a significant role in the development and persistence of HIV-associated …
Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and …
S Khalilieh, KL Yee, R Sanchez, SA Stoch… - Clinical Drug …, 2020 - Springer
Abstract Doravirine (MK-1439) is a novel non-nucleoside reverse transcriptase inhibitor
indicated for the combination treatment of human immunodeficiency virus type-1 (HIV-1) …
indicated for the combination treatment of human immunodeficiency virus type-1 (HIV-1) …
Prevalence and Factors Associated with Dyslipidemia Among People Living with HIV/AIDS on Follow-Up Care at a Tertiary Care Hospital in Ethiopia: A Cross …
A Assefa, AA Abiye, TA Tadesse… - Drug, Healthcare and …, 2023 - Taylor & Francis
Background Despite its importance as a major risk factor for cardiovascular disease,
dyslipidemia remains poorly characterized in the African population. Objective To assess the …
dyslipidemia remains poorly characterized in the African population. Objective To assess the …
Results of a doravirine-atorvastatin drug-drug interaction study
S Khalilieh, KL Yee, RI Sanchez… - Antimicrobial Agents …, 2017 - Am Soc Microbiol
Doravirine is a novel, highly potent, nonnucleoside reverse transcriptase inhibitor that is
administered once daily and that is in development for the treatment of HIV-1 infection. In …
administered once daily and that is in development for the treatment of HIV-1 infection. In …
Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy
N Tarantino, F Santoro, L De Gennaro… - Vascular health and …, 2017 - Taylor & Francis
Lipids disorder is the principal cause of atherosclerosis and may present with several forms,
according to blood lipoprotein prevalence. One of the most common forms is combined …
according to blood lipoprotein prevalence. One of the most common forms is combined …
Inhibition of CYP2B6 by medicinal plant extracts: implication for use of efavirenz and nevirapine-based highly active anti-retroviral therapy (HAART) in resource-limited …
Highly active antiretroviral therapy (HAART) has greatly improved health parameters of HIV
infected individuals. However, there are several challenges associated with the chronic …
infected individuals. However, there are several challenges associated with the chronic …
[HTML][HTML] Changes in lipid indices in HIV+ cases on HAART
S Ji, Y Xu, D Han, X Peng, X Lu… - BioMed Research …, 2019 - hindawi.com
We assess long-term changes in lipid levels in human immunodeficiency disease-(HIV-)
infected patients undergoing highly active antiretroviral treatment (HAART) and their …
infected patients undergoing highly active antiretroviral treatment (HAART) and their …